Last reviewed · How we verify
NCT02683252: AFRONT
Musculoskeletal Non-tumoral Pathology Quantitative Perfusion
NA trial testing T1 mapping and MR perfusion acquisition in Osteonecrosis in 400 participants. Status unknown.
12 February 2019
Quick facts
| Lead sponsor | Central Hospital, Nancy, France |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 400 |
| Start date | 12 February 2016 |
| Primary completion | 12 February 2019 |
| Estimated completion | 12 February 2020 |
| Sites | 2 locations across France |
Drugs / interventions tested
- T1 mapping and MR perfusion acquisition
Conditions studied
- Osteonecrosis — all drugs for Osteonecrosis →
- Pseudarthrosis — all drugs for Pseudarthrosis →
- Compartment Syndrome — all drugs for Compartment Syndrome →
Sponsor
Central Hospital, Nancy, France
Who can join
18 and older, any sex, with Osteonecrosis or Pseudarthrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Study on quantitative perfusion parameters acquired on MR imaging of patients with non-tumoral pathology of the musculoskeletal system.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02683252
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Osteonecrosis
Currently open trials in the same condition.
- NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
- NCT07471880 — A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage Osteonecrosis of the Femoral Head · Phase 2 · active not recruiting
- NCT05734651 — PROMIS Evaluation Study · recruiting
- NCT05283148 — Sickle Cell Disease (SCD) Bone Pain Study · NA · active not recruiting
- NCT05603728 — Exactech Shoulder Post Market Clinical Follow-up Study · recruiting
Other Central Hospital, Nancy, France trials
Trials by the same sponsor.
- NCT06452290 — PET Biomarker Study for Antidepressant Response Prediction in Major Depressive Disorder · NA · not yet recruiting
- NCT07518498 — Hypnosis During Mechanical Ventilation Weaning · NA · not yet recruiting
- NCT07471334 — Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies · NA · not yet recruiting
- NCT07414667 — Primary Sjögren's Syndrome: Impact of Quantitative Anti-Ro52 Antibody Analysis on Patient Prognosis and Stratification ( · not yet recruiting
- NCT07415759 — Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02683252 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Central Hospital, Nancy, France
- Last refreshed: 23 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02683252.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing